Tim-3 expression in Tumour-associated macrophages: A new player in HCC progression

Gut

Volumn 64, Issue 10, 2015, Pages 1502-1503

  Flecken, Tobias ^a   Sarobe, Pablo ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; SORAFENIB; T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN CONTAINING MOLECULE 3; TIM 3 PROTEIN; UNCLASSIFIED DRUG; RNA; TRANSFORMING GROWTH FACTOR BETA; VIRUS RECEPTOR;

CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER STAGING; DRUG EFFECT; DRUG TARGETING; GENE SILENCING; HUMAN; LIVER CELL CARCINOMA; MACROPHAGE FUNCTION; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; EXPERIMENTAL LIVER NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MACROPHAGE ACTIVATION; MALE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MACROPHAGE ACTIVATION; MALE; RECEPTORS, VIRUS; RNA, NEOPLASM; TRANSFORMING GROWTH FACTOR BETA;

EID: 84941364170     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2014-309094     Document Type: Note

References (10)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27.
2. Hernandez-Gea V, Toffanin S, Friedman SL, et al. Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma. Gastroenterology 2013;144:512-27.
3. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129-40.
4. Capece D, Fischietti M, Verzella D, et al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. BioMed Res Int 2013;2013:187204.
5. Yan W, Liu X, Ma H, et al. Tim-3 fosters HCC development by enhancing TGF-β-mediated macrophages alternative activation. Gut 2015;64: 1593-604.
6. Li H, Wu K, Tao K, et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2012;56:1342-51.
7. Anderson AC Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2014;2:393-8.
8. Ferris RL, Lu B, Kane LP. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J Immunol 2014;193:1525-30.
9. Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010;207:2187-94.
10. Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011;71:3540-51.